Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $24.7 million.

  • Century Therapeutics' Cash from Investing Activities fell 3706.22% to $24.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.7 million, marking a year-over-year increase of 22623.81%. This contributed to the annual value of $47.5 million for FY2024, which is 2232.87% down from last year.
  • As of Q3 2025, Century Therapeutics' Cash from Investing Activities stood at $24.7 million, which was down 3706.22% from $32.5 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Cash from Investing Activities high stood at $39.2 million for Q3 2024, and its period low was -$44.0 million during Q1 2022.
  • For the 4-year period, Century Therapeutics' Cash from Investing Activities averaged around $12.0 million, with its median value being $18.6 million (2023).
  • Within the past 5 years, the most significant YoY rise in Century Therapeutics' Cash from Investing Activities was 82954.71% (2024), while the steepest drop was 58557.5% (2024).
  • Over the past 4 years, Century Therapeutics' Cash from Investing Activities (Quarter) stood at -$4.3 million in 2022, then soared by 535.36% to $18.6 million in 2023, then skyrocketed by 64.52% to $30.6 million in 2024, then decreased by 19.39% to $24.7 million in 2025.
  • Its Cash from Investing Activities was $24.7 million in Q3 2025, compared to $32.5 million in Q2 2025 and $27.9 million in Q1 2025.